Ramiro Ribeiro - 05 Jan 2026 Form 4 Insider Report for EyePoint, Inc. (EYPT)

Role: Chief Medical Officer
Signature: /s/ Ron Honig, Attorney-in-Fact
Issuer symbol: EYPT
Transactions as of: 05 Jan 2026
Net transactions value: -$485,714
Form type: 4
Filing time: 07 Jan 2026, 16:07:22 UTC
Previous filing: 06 Jan 2026
Next filing: 18 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ribeiro Ramiro	Chief Medical Officer	C/O EYEPOINT, INC, 480 PLEASANT STREET, SUITE C400, WATERTOWN	/s/ Ron Honig, Attorney-in-Fact	07 Jan 2026	0002013623

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EYPT	Common Stock	Options Exercise	$241,605	+29,250	+220%	$8.26	42,544	05 Jan 2026	Direct
transaction	EYPT	Common Stock	Sale	$727,319	-42,544	-100%	$17.10	0	05 Jan 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EYPT	Stock Option (Right to Buy)	Options Exercise	$0	-29,250	-25%	$0.000000	87,750	05 Jan 2026	Common Stock	29,250	$8.26	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.68 to $17.51. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.68 to $17.51. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.